<DOC>
	<DOCNO>NCT00624078</DOCNO>
	<brief_summary>This treatment protocol enable therapeutic use Anascorp management systemic manifestation scorpion sting envenomation , patient antivenom would otherwise unavailable . The working hypothesis follow : 1 . The investigational antivenom safe treatment scorpion sting envenomation . 2 . The investigational antivenom effective treatment scorpion sting envenomation .</brief_summary>
	<brief_title>Treatment Protocol Use Anascorp™ Patients With Scorpion Sting Envenomation</brief_title>
	<detailed_description>The purpose Open Label , Multi-Center Treatment Protocol , phase III trial examine safety efficacy Anascorp , treatment patient envenom scorpion sting . The treatment protocol , include 25 Arizona site , increase total number subject receive Anascorp™ , provide supplemental safety data review process . At time , prevent public health crisis rural Arizona replace dwindle supply local antivenom BLA approve . Patients arrive emergency clinic present scorpion sting symptom evaluate treatment Anascorp . Each patient qualify entry study , accord inclusion/exclusion criterion , assign patient number sequential order entry . Approximately 100 patient could enrol study per year . After informed consent obtain , baseline history physical obtain documented patient 's chart . This include evaluation symptom systemic scorpion envenomation . The patient 's vital sign ( blood pressure , pulse respiration ) take . The patient question concomitant medication . Demographic data also collect . Three vial Anascorp administer total volume 50 mL , intravenous less 10 minute permit IV access . If clinically indicate systemic sign , second dose ( one vial ) administer clinically indicate systemic sign . One additional dose may administer 30 minute later indicate clinically significant sign envenomation . When clinically significant sign absent least 30 minute , final physical assessment take place patient discharge home . Twenty four hour fourteen day Anascorp™ treatment , patient monitor sign symptom adverse event , include acute hypersensitivity reaction ( anaphylactic and/or anaphylactoid reaction ) delay serum sickness . All patient receive study drug include final analysis . For individual patient , study start time consent sign end 14 day telephone interview . The outcome assess 14 day discharge telephone interview . Concomitant therapy medication may use time need . All concomitant medication must document CRF time entry study 14 day follow telephone interview..</detailed_description>
	<mesh_term>Bites Stings</mesh_term>
	<mesh_term>Poisoning</mesh_term>
	<mesh_term>Scorpion Stings</mesh_term>
	<mesh_term>Antivenins</mesh_term>
	<criteria>Males female age present emergency treatment clinically important systemic sign scorpion sting envenomation Signed write Informed Consent patient legal guardian Allergy horse serum</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>faboterapics</keyword>
	<keyword>treatment</keyword>
	<keyword>scorpion sting</keyword>
	<keyword>envenomation</keyword>
</DOC>